Glioblastomas are a type of central nervous system tumor in the brain or spinal cord characterized by their aggressiveness and rapid proliferation . Utilizing CAR T-cell therapy as a treatment for these tumors has shown promise for eliminating the malignant cells by engineering each patient's T cells to express specific CAR that specialize in recognizing glioblastoma-associated antigens . The CAR T-cells developed by Xu et al. have particular single-chain variable fragment (scFv) antibodies on the surface of their CAR . These are humanized third-generation CAR T cells that can interact with the IL-13Ra2 receptors of glioblastoma cells .